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Many experimental and clinical studies have confirmed a continuous cross-talk between
both sympathetic and parasympathetic branches of autonomic nervous system and
inflammatory response, in different clinical scenarios. In cardiovascular diseases,
inflammation has been proven to play a pivotal role in disease progression, pathogenesis
and resolution. A few clinical studies have assessed the possible inter-relation between
neuro-autonomic output, estimated with heart rate variability analysis, which is the
variability of R-R in the electrocardiogram, and different inflammatory biomarkers, in
patients suffering from stable or unstable coronary artery disease (CAD) and heart failure.
Moreover, different indices derived from heart rate signals’ processing, have been proven
to correlate strongly with severity of heart disease and predict final outcome. In this
review article we will summarize major findings from different investigators, evaluating
neuro-immunological interactions through heart rate variability analysis, in different groups
of cardiovascular patients. We suggest that markers originating from variability analysis
of heart rate signals seem to be related to inflammatory biomarkers. However, a lot of
open questions remain to be addressed, regarding the existence of a true association
between heart rate variability and autonomic nervous system output or its adoption for
risk stratification and therapeutic monitoring at the bedside. Finally, potential therapeutic
implications will be discussed, leading to autonomic balance restoration in relation with
inflammatory control.
Keywords: heart rate variability, inflammation, autonomic nervous system, coronary artery disease, cardiovascular
disease, mortality
INTRODUCTION
Systemic inflammation is a normal response to altered home-
ostasis and has an important role in several pathophysiologi-
cal processes, such as infection or trauma. It is characterized
by the endocrine release of different cytokines, such as tumor
necrosis factor α (TNF-α) and interleukin-1 (IL-1), IL-4, IL-6,
Abbreviations: ACE, angiotensin-converting enzyme; ACTH, adrenocorti-
cotropin hormone; ANS, autonomic nervous system; ATRAMI, Autonomic Tone
and Reflexes After Myo-cardial Infarction Study; CAD, coronary artery disease;
CHF, congestive heart failure; CNS, central nervous system; CRP, C-reactive pro-
tein; DHA, docasah-exaenoic acid; DMN, dorsal motor nucleus of the vagus; DVC,
dorsal vagal complex; ECG, electrocardiogram; EPA, eicosapentaenoic acid; FFT,
Fast Fourier trans-formation; HPA, hypothalamo-pituitary-adrenal axis; HRV,
heart rate variability; HF, high frequency; LF, low frequency; LVEF, left ventricular
ejection fraction; MODS, multiple organ dysfunction syndrome; NYHA, New York
Heart Association; NTS, nucleus tractus solitaries; pNN50, proportion derived
from dividing NN50 (number of interval differences of successive intervals greater
than 50ms) by the total NN intervals; PSD, power spectrum density; PUFA,
polyunsaturated fatty acids; PVN, paraventricular nucleus; RMSSD, square root of
the mean squared differences of successive intervals; RVLM, rostral ventrolateral
medulla; TNF-α, tumor necrosis factor α; SAN, sinus atrial node; SDNN, standard
deviation of the normal-to-normal intervals which is the square root of the
variance; SD, standard deviation; SNS, sympathetic nervous system; THS, Twins
Heart Study; ULF, ultra low frequency; VLF, very low frequency; WBC, white
blood cell count.
IL-10, and many others, normally confined to paracrine regula-
tion of a local inflammatory response (Koj, 1997; Sporn, 1997).
Apart from their involvement in local and systemic inflammation,
cytokines may induce activation of brain-derived neuroendocrine
immunomodulatory responses. Neuro-endocrine pathways, such
as hypothalamo-pituitary-adrenal (HPA) axis and both the sym-
pathetic and parasympathetic divisions of the autonomic nervous
system (ANS) are powerful modulators of inflammation, typically
through an anti-inflammatory balancing mechanism (Reichilin,
1993; Webster et al., 2002).
Recently, it has been demonstrated that subclinical inflam-
mation and the con-centration of inflammatory markers, such
as cytokines, correlate strongly to cardio-vascular mortality and
morbidity in both healthy subjects and in those with known coro-
nary artery disease (CAD) (Phillips et al., 1992; Ridker et al.,
1997). Furthermore, vascular inflammation plays a critical role
in the initiation, evolution, and rupture of atherosclerotic plaque
(Ross, 1993).
In the healthy state there is some degree of stochastic vari-
ability in physiologic variables, such as heart rate (heart rate
variability). This variability is a measure of complexity that
accompanies healthy systems and has been suggested to be
responsible for their greater adaptability and functionality related
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to pathologic systems (Buchman, 2002). Studying physiologi-
cal signals of patients can easily identify ”hidden” information
concerning inherent dynamics and overall variability within a
time series. Recognition that physiologic time series contain such
information defies traditional mechanistic approaches based on
conventional biostatistical methodologies and has fueled grow-
ing interest in applying techniques from statistical physics for the
study of living organisms (Seely and Christou, 2000). Through
those techniques different “physiomarkers” can be estimated that
fulfill the requirements of contemporary medicine for better
and more accurate early warning signs, since they are based
on high-frequency measurements and are much easier to mea-
sure at the bedside (Seely and Christou, 2000). In this respect,
a number of international databases and different processing
methods of heart rate signals have been developed with free
access from different investigators, such as the Web Site Physionet
(www.physionet.org).
On the contrary, it has been repeatedly demonstrated that
various “biomarkers” such as cytokines, exhibit marked interde-
pendence, pleiotropy (multiple effects) and redundancy (multiple
cytokines with the same effect) (Friedland et al., 1996). At the
same time, their plasma concentrations fluctuate from day to day
and correlate poorly with classic physiologic variables in differ-
ent groups of patients (Friedland et al., 1996; Seely and Christou,
2000; Buchman, 2002). Furthermore, biomarkers are difficult to
obtain routinely at the bedside. In addition, the financial cost
of various immunoassay techniques for their detection in blood
samples tends to become an inhibiting factor for their exten-
sive use, as diagnostic or even prognostic tools, in many Medical
Centers.
NEURO-IMMUNOLOGICAL CROSS-TALK AND HEART RATE
VARIABILITY ANALYSIS
The pathophysiological link between the communication
between the Central Nervous System (CNS) and the immune-
regulated inflammation is the capability of the brain to monitor
and to affect at the same time the immune status. The first
mechanism relies upon activation of vagus nerve afferent fibers
that signal the brain that inflammation is occurring. Different
kind of mediators such as cytokines can activate visceral vagus
afferent fibers which terminate within the dorsal vagal complex
(DVC) of the medulla oblongata. The DVC consists of the nucleus
tractus solitarius (NTS), the dorsal motor nucleus of the vagus
(DMN) and the area postrema (AP) (Berthhoud and Neuhuber,
2000). Ascending projections from the NTS reach hypothalamic
paraventricular nucleus (PVN), which is associated with the
synthesis and release of corticotropin releasing hormone (CRH).
This factor induces the production of adrenocorticotropin
hormone (ACTH) from the anterior pituitary, which is the main
inducer of the synthesis of immuno-suppressive glucocorticoids
from the adrenal cortex. Projections from NTS are connected
to the DMN and to rostral ventrolateral medulla (RVLM).
This region increases firing of the noradrenergic preganglionic
neurons in the spinal cord (Tracey, 2007).
The brain can affect the immunological status through the
activation of the HPA axis and increased outflow of sympa-
thetic (SNS) and parasympathetic nervous system. The SNS
activation during the early stages of stress induces local inflam-
matory response through α2–subtype adrenoreceptor stimula-
tion by norepinephrine (NE), whereas stimulation of β2-subtype
adrenoreceptor-cAMP-protein kinase A pathway is associated
with an inhibition of pro-inflammatory cytokines’ production
(van der Poll et al., 1996; Elenkov et al., 2000; Zhou et al.,
2001). It seems that SNS activation protects the organism from
the detrimental effects of pro-inflammatory cytokines, while it
can increase local inflammatory response (Chrousos, 1995). In
addition to the SNS, a link between the parasympathetic part
of the ANS and immune-regulatory processes has been sug-
gested (Tracey, 2002). It has been demonstrated that acetyl-
choline decreases TNF-α production by endotoxin-stimulated
human macrophage cultures, through α7-subunit of the nico-
tinic acetylcholine receptor (Wang et al., 2003; de Jonge et al.,
2005). The vagus nerve cholinergic signaling interacts with the
above receptor on immune cells in the spleen and inhibits TNF-
α production and release into the circulation (Huston et al.,
2006). Acetylcholine is also effective in suppressing other pro-
inflammatory cytokines such as IL-1β, IL-6, and high mobility
group box 1 (HMGB1) protein (Wang et al., 2004). This ”cholin-
ergic anti-inflammatory pathway” is responsible for a ”hard-
wired” connection between the nervous and immune systems and
is considered, as the primary component of the “immuno-reflex.”
A more complete understanding of these reflexes can yield insight
into both pathophysiological pathways and therapeutic strategies
in many pathological processes, including infections, sepsis and
cardiovascular diseases (Tracey, 2002, 2007).
In conclusion, there is strong evidence that CNS controls
body’s systemic response to inflammation. Recently, different
clinical studies investigating a possible association between ANS
outflow and various inflammatory indices in patients with heart
diseases have appeared in the literature (Aronson et al., 2001;
Malave et al., 2003; Janszky et al., 2004; Shehab et al., 2004;
Hamaad et al., 2005; Lanza et al., 2006; Madsen et al., 2007;
Nolan et al., 2007; Psychari et al., 2007; von Känel et al., 2011).
The aim of these studies was to measure ANS activity through a
set of different “physio-markers” and correlate them with vari-
ous biomarkers that can indirectly assess inflammatory response
in different clinical scenarios, such as CAD (Janszky et al., 2004;
Hamaad et al., 2005; Lanza et al., 2006; Madsen et al., 2007; Nolan
et al., 2007; Psychari et al., 2007; von Känel et al., 2011) and heart
failure (Aronson et al., 2001; Malave et al., 2003; Shehab et al.,
2004). Moreover, the prognostic value of such measurements was
tested in different groups of patients with cardiovascular diseases,
in terms of mortality and risk of rehospitalization.
The best “physiomarkers” are obtained from analysis of heart
rate variability (HRV); that is, the variability of R-R series in
the electrocardiogram (ECG), and its frequency components
(Lombardi et al., 1987; Task Force, 1996). Beat-to-beat fluctua-
tions reflect the dynamic response of the cardiovascular control
systems to a host of naturally occurring physiological perturba-
tions. A variety of animal and human research has established two
clear frequency bands in heart rate signals. These bands include
high frequency oscillations, between 0.15 and 0.4Hz that are
associated with respiration, and bands with a lower frequency
range, below 0.15Hz (Task Force, 1996). Akselroad et al. (1981)
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introduced power spectrum analysis of heart rate fluctuations
in order to quantify beat-to-beat cardiovascular control. Power
spectrum density (PSD) analysis provides the basic information
of how power (variance) distributes as a function of frequency
(Akselroad et al., 1981; Malik and Camm, 1993). In 1996, the Task
Force of the European Society of Cardiology and the Northern
American Society of Pacing and Electrophysiology published
guidelines regarding standardization of nomenclature, specifica-
tion of methods of measurement, definition of physiological and
pathophysiological correlates, description of clinical applications
and identification of different areas for future research.
The association of higher risk of post-infarction mortality with
reduced HRV was first shown by Wolf et al. (1978). The clinical
importance of HRV became appreciated in the late 1980s, when
it was demonstrated that low HRV was a strong and independent
predictor of mortality after an acute myocardial infarction (MI)
(Kleiger et al., 1987; Lombardi et al., 1987).
MEASUREMENY OF HEART RATE VARIABILITY
The RR variations may be evaluated by a number of methods:
TIME DOMAIN METHODS
Time domain methods determine heart rate or RR intervals in
continuous ECG records. Each QRS complex is detected and
the normal-to-normal (NN) intervals (all intervals between adja-
cent QRS complexes) are calculated. Other time domain variables
include the mean NN interval, the mean heart rate or the differ-
ence between the longest and the shortest NN interval, as well.
The simplest of these metrics is the standard deviation of the
NN intervals (SDNN), which is the square root of the variance.
However, it should be emphasized that SDNN becomes less accu-
rate with shorter monitoring periods. The most commonly used
time domain methods are the square root of the mean squared
differences of successive NN intervals (RMSSD), the number of
interval differences of successive NN intervals greater than 50ms
(NN50) and the proportion derived from dividing NN50 by the
total NN intervals (pNN50) (Akselroad et al., 1981; Task Force,
1996; Table 1).
FREQUENCY DOMAIN METHODS
Spectral analysis of heart rate partitions HRV into its frequency
components. Most commonly used methods are Fast Fourier
Transformation (FFT) and auto-regressive modeling. FFT dis-
plays in a plot the relative contribution (amplitude) of each fre-
quency. This plot includes at least three peaks.Fast periodicities in
Table 1 | HRV metrics in time domain.
SDNN Standard deviation of all N-N intervals
SDNN index Average of the standard deviations of N-N intervals for
each 5-min period
SDANN Standard deviation of the average N-N intervals for each
5-min period over 24 h
NN50 Number of N-N intervals differing by >50ms from the
preceding interval
pNN50 Percentage of adjacent cycles that are >50ms apart
RMSSD Root mean square of successive differences in ms
the range 0.15–0.4Hz [high frequency (HF)] are largely due to the
influence of the respiratory phase on vagal tone. Low-frequency
periodicities (LF), in the region of 0.04–0.15Hz, are produced by
baroreflex feedback loops, affected by both sympathetic and para-
sympathetic modulation of the heart, whereas very low frequency
periodicities (VLF), in the frequency range between 0.003 and
0.04Hz and ultra low frequencies (ULF, <0.003Hz) have been
variously ascribed to modulation by chemoreception, thermo-
regulation and the influence of vasomotor activity. The area under
the power spectral curve (power) in a particular frequency band is
considered to be a measure of HRV at that frequency, whereas the
LF/HF ratio has been suggested as an indirect index of sympatho-
vagal balance (Task Force, 1996). According to the report of the
Task Force, the analyzed ECG signals must satisfy several technical
requirements in order to obtain reliable information. The opti-
mal sampling frequency range should be between 250 to 500Hz.
Ectopic beats, arrhythmic events, missing data and noise effects
should be properly filtered and omitted. Frequency domainmeth-
ods must be preferred in cases of short term investigations. The
recordings should last for at least 10 times the wavelength of the
lower frequency bound, thus recordings of ∼1min can assess the
HF component of HRV while 2min are needed for the LF com-
ponent. In conclusion, 5-min recordings are preferred, unless the
aim of the study dictates a different design (Akselroad et al., 1981;
Lombardi et al., 1987; Task Force, 1996; Table 2).
ORIGIN OF HEART RATE VARIABILITY COMPONENTS
HIGH FREQUENCY OSCILLATIONS
The cyclic variations in intrathoracic pressure perturbate venous
return, cardiac out-put and thus, blood pressure. These changes
are sensed by baroreceptors and result in changes in autonomic
activity to the heart. These perturbations are mediated via the
vagus nerve as atropine administration abolishes high frequency
oscillations in heart rate (Akselroad et al., 1981). It seems that
a major cause of respiratory sinus arrhythmia (RSA) is a cen-
tral coupling of respiratory drive to cardiac vagal motor neurons.
However, the changes in vagal activity are partly induced by
baroreceptor sensing of respiratory oscillations in blood pres-
sure and reflect all components of the baroreflex loop (DeBoer
et al., 1987). In addition, factors such as reduced respiratory
capacity and body position may alter the amplitude of high fre-
quency oscillations in blood pressure and subsequently the HF
component of heart rate signals (Malpas, 2002). Thus, heart
rate variability analysis cannot be used for comparisons between
different patient groups as there is a need for controlling ven-
tilation for both rate and depth. Moreover, and since there is
marked inter-individual variation in the relationship between
HRV and parasympathetic effect, differences in HRV between
individuals may reflect differences in this relationship, as was pos-
tulated by Goldberger (Goldberger et al., 2001). In this respect,
Table 2 | HRV metrics in frequency domain.
ULF (ultra low frequency) ms2 24h recordings ≤0.003Hz
VLF (very low frequency) ms2 24h and 5-min recordings −0.003–0.04Hz
LF (low frequency) ms2 24h and 5-min recordings −0.04–0.15Hz
HF (high frequency) ms2 24h and 5-min recordings −0.15–0.4Hz
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this relationship in humans was described by a quadratic func-
tion in which there is an initial ascending limb, where HRV
increases in parallel with vagal effect until it reaches a plateau
level. Beyond this level, HRV decreases with further augmentation
of vagal tone, probably due to a saturated HRV response upon
intense autonomic stimulation (Goldberger et al., 2001). Finally,
age and sex-related differences have also been associated with this
variability (Goldberger et al., 2001).
LOW FREQUENCY OSCILLATIONS
The LF component of HRV is probably the most contentious
aspect with respect to cardiovascular variability. There are two
opposing theories in the literature proposing different potential
origins: (1) the central oscillator theory (Montano et al., 1996)
and (2) the baroreflex feedback loop theory (Lanfranchi and
Somers, 2002). According to the first theory, it is believed that
LF oscillations reflect sympathetic tone and are generated by the
brain stem circuits. In cats, Montano (Montano et al., 1996) ana-
lyzed the dis-charges of single sympathetic neurons located in the
rostral ventrolateral medulla and caudal ventrolateral medulla.
He observed activity at 0.12Hz, which was positively correlated
with heart rate and blood pressure variability. As the above oscil-
lations remained after sino-aortic and vagal resection, it was
assumed that the central nervous system is able to generate such
oscillations.
According to the baroreflex feedback loop theory, a change
in blood pressure is sensed by arterial baroreceptors, resulting
in heart rate adjustment through the central nervous system
and via both the fast vagal and the slower sympathetic actions
(Lanfranchi and Somers, 2002). At the same time, baroreceptors
induce a slow sympathetic withdrawal from the vessels. The delay
in the sympathetic branch of the baroreflex in turn determines a
new oscillation, which is sensed by the baroreflex and induces a
new oscillation in heart rate. It has been also proposed that the
LF oscillation arises from the interaction of slow sympathetic and
fast vagal responses, where baroreflex buffering of the slow respi-
ratory induced blood pressure oscillations results in resonant low
frequency oscillations, due to the delay in the slow conducting
sympathetic loop of the baroreflex (DeBoer et al., 1987).
In conclusion, it must be stressed that the low frequency
oscillations of heart rate reflect the ability of the individual com-
ponents of the baroreflex feedback loop to respond to different
inputs that can alter the power of such oscillations and they are
not just a measure of sympathetic nerve activity.
INTRACARDIAC ORIGIN OF HRV
The reasons for reduced HRV during cardiovascular diseases
have been debated and two theories have been developed. The
first theory focuses on reduction of vagal tone and has been
introduced by Akselroad et al. (1981). The second theory devel-
oped by Goldberger and colleagues (2002) states that normal
physiology has fractal-like properties with high levels of complex-
ity that explain phenomena such as HRV. Its reduction during
severe disease reflects a “de-complexification,” mostly attributed
to uncoupling between different restorative mechanisms (Godin
and Buchman, 1996). In addition, accumulating evidence from
both in vitro and ex vivo experiments support a potential third
mechanism (Griffin et al., 2005), which is associated with an
intracardiac origin of HRV. According to this hypothesis, sinus
atrial node (SAN) cells can be viewed as an amplifier of various
input signals (Zaza and Lombardi, 2001). During cardiovascular
diseases, an unfavorablemetabolic milieu could affect ion channel
gating properties or membrane receptor densities, with signifi-
cant impact upon level and variability of pacemaker activity. In
addition, a possible reduced responsiveness of SAN cells to exter-
nal stimuli could also negatively affect HRV (Zaza and Lombardi,
2001).
Moreover, different clinical studies in heart transplant recip-
ients have found evidence for heart rate fluctuations originating
from the heart itself (Hrushesky et al., 1984; Bernardi et al., 1990).
Bernardi studied intrinsic mechanism regulating HRV in both
transplanted and intact heart during exercise (Bernardi et al.,
1990). He found that at peak exercise a non-autonomic mecha-
nism, probably intrinsic to the heart muscle, may determine heart
rate fluctuations in synchrony with ventilation, in transplanted as
well as in intact hearts. Hrushesky and colleagues (1984) quanti-
fied respiratory sinus arrhythmia and found that individuals with
a transplanted heart had resting RSA values similar to healthy
subjects.
In conclusion, there is marked inter-individual variation
between HRV response and different levels of autonomic stimula-
tion. Basal autonomic activity, age and sex differences, alterations
in expression of ion channel activity or autonomic receptors
could be responsible for individualized curves, relating auto-
nomic effects to HRV (Eckberg, 1997; Goldberger et al., 2001). In
addition, LF/HF ratio has been criticized as an indirect measure
of sympathovagal balance, reflecting rather autonomic fluctu-
ations and not absolute measures of autonomic nerve traffic
(Eckberg, 1997; Billman, 2013). Thus, interpretation of differ-
ent studies investigating HRV alterations in different groups of
patients should be cautious since variability in time of record-
ings and methods for HRV analysis, as well as heterogeneity of
studying population, limit generalization of their findings.
CLINICAL IMPLICATIONS OF ALTERED HEART RATE
VARIABILITY
The first large prospective population study that reported the sig-
nificant prognostic value of low HRV after an acute myocardial
infarction was the Autonomic Tone and Reflexes After Myocardial
Infarction Study (ATRAMI) (La Rovera et al., 1998), and included
1284 patients with a recent (<28 days) myocardial infarction. A
24 h Holter recording was done to quantify HRV (using SDNN
values) and ventricular arrhythmias. Low values of HRV (SDNN
< 70ms) carried a significant multivariate risk of cardiac mor-
tality. Furthermore, the association of low SDNN with left ven-
tricular ejection fraction (LVEF) <35% carried a relative risk of
6.7, compared with patients with LVEF above 35%. Investigators
from the Framingham Heart Study (Tsuji et al., 1994) computed
HRV time and frequency domain measures in 736 patients and
correlated them with all-cause mortality during 4 years of follow-
up. They concluded that HRV offers prognostic information
independent of that provided by traditional risk factors.
During the Zutphen study (Dekker et al., 1997), 885 middle-
aged (40–60 years old) and elderly Dutch men (aged 65–85)
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were followed from 1960 until 1990, whereas SDNN was deter-
mined from the resting 12-lead ECG. It was shown that low
HRV is predictive of mortality from all causes, indicating that
it can be used as an index of compromised health in the gen-
eral population. It seems that the predictive value of low HRV
is independent of other factors, such as depressed left ventric-
ular ejection fraction and presence of late potentials (Kleiger
et al., 1987; Lombardi et al., 1987). In addition, retrospective
ECG data analysis from 127 patients included in the Veterans
Affairs’ Survival Trial of Antiarrhythmic Therapy in Congestive
Heart Failure (CHF) (Bilchick et al., 2002) demonstrated that CHF
patients with SDNN<65.3ms had a significantly increased risk of
sudden death. Moreover, this study demonstrated that every 10ms
increase in SDNN conferred a 20% decrease in risk of mortality.
HEART RATE VARIABILITY AND INFLAMMATORY
BIOMARKERS IN CARDIOVASCULAR DISEASES
The relationship between HRV and inflammation has been stud-
ied mainly in patients with acute or stable CAD, CHF and
metabolic syndrome with impaired glucose tolerance (Brunner
et al., 2002). The inflammatory biomarkers that were used
included C-reactive protein (CRP), TNF-α, IL-6 and white blood
cell count (WBC).
PATIENTS WITH CORONARY ARTERY DISEASE
Hamaad et al. (2005) tested the association between time and
frequency domain indices of HRV and circulating IL-6, high sen-
sitivity CRP (hs-CRP) and white cell counts, in a sample of 100
patients with proven acute coronary syndrome. In addition, they
compared these metrics with healthy controls (n = 49) and esti-
mated possible relationships on repeated measures at 4 months
in recovery (n = 51). They found modest negative correlations
between all inflammatory biomarkers and mainly SDNN, VLF
and LF power. The strongest associations were seen betweenWBC
and SDNN (r = −0.351). However, relationships did not persist
on multivariate analyses after a 4-month period. According to
the authors, the correlations were observed largely among HRV
indices reflecting sympathetic activity, suggesting that the inflam-
matory response in acute coronary events may be associated with
sympathetic activation instead of vagal withdrawal. Furthermore,
leukocytosis observed in these patients seems to be a potential
source of pro-inflammatory cytokines within the atheromatous
plaque and might induce a potential rupture.
In another study, Lanza and colleagues (2006) assessed HRV
and measured CRP serum levels within 24 h of admission in
531 patients with unstable angina pectoris. They found a sig-
nificant negative correlation between CRP levels and all HRV
metrics derived from both time and frequency domain, with the
highest correlation coefficient with SDNN and VLF. After cat-
egorizing patients into 4 subgroups according to CRP quartile
levels, significantly lower HRV values were found in the upper
CRP quartile. The subsequent multivariate analysis revealed that
SDNN and VLF were the most significant predictors of increas-
ing CRP, whereas CRP was a strong predictor of impaired ANS
activity as well.
In a study including patients with suspected CAD, Madsen
et al. (2007) enrolled 269 subjects referred for elective coronary
angiography. They found that SDNN of heart rate signals was
significantly higher in the lower CRP quartile compared to the
upper one, whereas associations were stronger for patients with
a previous myocardial infarction and with significant coronary
stenoses.
In a similar study (Nolan et al., 2007), a negative correla-
tion between CRP andHRV frequency components was reported,
whereas a decreased HF power (reflecting vagal tone) in the high
CRP quartile, compared to the lowest one, was found. In the
study by Janszky and colleagues (2004) that included only female
patients who survived hospitalization for acute myocardial infarc-
tion and were evaluated 1 year after the event, levels of IL-6
showed an inverse relation with all HRV frequency measures,
except for HF. However, this relationship, as well as the associ-
ation between CRP levels and IL-1 receptor antagonist (IL-1ra)
with HRV indices was non-significant. Psychari et al. (2007) also
reported a strong inverse association between CRP and several
HRV indices (SDNN, HF, and LF) in post-MI patients and after
adjustment for left ventricular function.
Recently, von Känel et al. (2011) investigated the association
between HRV measured in the time domain, CRP, IL-6 and fib-
rinogen, in a cohort of 862 subjects recruited from the Heart and
Soul Study, which assessed health outcomes in 1.024 outpatients
with stable CAD. They found that SDNN was inversely and sig-
nificantly associated with inflammatory indices, after adjustment
of all covariates.
PATIENTS WITH HEART FAILURE
In 2001, Aronson et al. (2001) evaluated for the first time the
relationship between HRV metrics derived from both time and
frequency domains and different biomarkers, such as IL-6, TNF-
α, and serum levels of norepinephrine, in 64 patients admit-
ted for decompensated chronic heart failure. TNF-α levels did
not correlate with any of the HRV indices. However, IL-6 was
inversely correlated with SDNN (r = −0.36), with total power
of heart rate signals and ULF (r = −0.37 and r = −0.43, respec-
tively). No correlation was found between IL-6 and time (pNN50
and RMSSD) or frequency domain (HF power) indices of vagal
activity.
Malave et al. (2003) examined HRV in relation to circulat-
ing levels of TNF-α, TNF-α receptors and norepinephrine in
10 controls, 15 patients with mild CHF and 14 subjects with
moderate heart failure. There was a significant inverse linear cor-
relation between increased levels of all biomarkers and SDNN,
LF and HF power among CHF patients. In addition, LF power
was more closely correlated with circulating levels of TNF-α
than was the HF component, whereas multiple linear regres-
sion analysis showed that TNF-α was a stronger predictor of
reduced HRV than was the circulating levels of norepinephrine.
The authors concluded that over-expression of TNF-α and sub-
sequent loss of β-adrenergic responsiveness contributes to the
decrease in HRV, observed in heart failure. According to find-
ings from experimental studies (Chung et al., 1990), TNF-αmight
inhibit β-adrenergic signal transduction through either activation
of Gi proteins or impairment of activation of Gs proteins, some-
thing that could be viewed as an adaptive mechanism in the early
stages of CHF, protecting cardiac myocytes from the deleterious
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actions of catecholamines. However, in the more advanced stages
of the disease, this mechanism could becomemaladaptive, leading
to a reduction in cardiac output (Mann et al., 1992).
Finally, in a small prospective study that included 34 patients
with CHF followed for a 2-year period with monthly CRP mea-
surements and 24-h Holter recordings, it was shown that five
unexpected deaths that occurred were preceded by progressive
increases in both CRP serum levels and autonomic dysfunction
(low HRV indices) (Shehab et al., 2004).
HEALTHY CONTROLS
As a part of the Copenhagen Holter study, that assessed the
value of 24-h Holter recording in the risk assessment of men
and women aged 55, 60, 65, 70, and 75 years with no appar-
ent heart disease, Sajadieh et al. (2004) investigated the asso-
ciations between time domain components of HRV, CRP and
WBC in 643 healthy men and women. They found that SDNN
was negatively correlated with smoking, inflammatory indices,
blood sugar, triglyceride concentration, female gender and dia-
betes. Moreover, in multivariate regression analysis, increased
heart rate and reduced HRV were significantly related to white
blood cell count and CRP. The reduction of SDNNwas attributed
to sympathetic predominance, whereas lack of any associa-
tion between inflammation and pNN50, which is considered
as a marker of vagal activity, indicates that reduced HRV is
mainly due to increased sympathetic activity rather than vagal
withdrawn.
From the Whitehall II cohort, a multicenter epidemiologic
investigation of over 5000 subjects, two studies (Owen and
Steptoe, 2003; Sloan et al., 2007) used sub-samples to examine the
relation between HRV indices derived from the frequency domain
and inflammation, in healthy subjects. In the first study, Sloan
found in a sample of 757 people, an inverse correlation between
CRP and IL-6 with both LH and HF components of HRV power
spectrum. In the second study, Owen and Steptoe did not find
any association between IL-6, TNF-α and time domain measures
of HRV, in a group of 211 healthy adults.
Other investigators (Albert et al., 2002) reported a strong pos-
itive association between CRP levels and the long-term risk of
sudden cardiac death, in case-control analysis among healthy
individuals, followed for 17 years in the Physician’s Health Study.
Men in the upper CRP quartile had a 2.8 fold increased risk of
sudden cardiac death compared to men in the lower quartile.
According to the authors, a low-grade inflammation involved in
atherosclerosis shifts ANS balance toward sympathetic activation,
making individuals more prone to ventricular arrhythmias and
sudden cardiac death.
The Twins Heart Study (THS) (Goldberg et al., 2002) was an
investigation of psychological, biological and behavioral risk fac-
tors for subclinical cardiovascular diseases in 7.369 middle-aged
male-male twin pairs, who served in the United States military
during the VietnamWar. From this registry, a cohort of 264 twins
free of symptomatic CAD was examined by Lampert et al. (2008),
for assessing possible associations between HRV, CRP, and IL-6.
They found an inverse relationship between frequency domain
HRVmetrics (except for HF) and both CRP and IL-6. These asso-
ciations persisted after adjustment for other traditional CAD risk
factors, such as smoking, hypertension, diabetes, high-density
lipoprotein (HDL) and depression.
A significant confounding factor of HRV analysis that has to
be considered in these studies includes the presence of depres-
sive symptoms and anxiety. It has been estimated that ∼12–20%
of hospitalized cardiac patients suffer from major depression,
whereas 15% of subjects following acute myocardial infarction
exhibit a posttraumatic stress disorder (Frasure and Lesperance,
2006; Garder and von Karel, 2006; Pizzi et al., 2008). In a 2-year
follow up prospective observational study, Pizzi investigated the
relation between time domain HRV indices, IL-6, TNF-α, CRP
and depression in a cohort of 415 subjects free of CADs, with at
least two CAD risk factors (age, male gender, current smoking,
hypertension, dislipidaemia). All HRV and inflammatory indices
were significantly associated with depression. Logistic regression
further showed that depressive individuals were more likely to
have a higher CRP and IL-6 and altered HRV (lower SDNN).
In a recent study of Kop and colleagues (2010) who recruited
908 patients, free of CAD, for a median follow-up period of 13.3
years, it was demonstrated that among depressed participants, HF
power of HRV was negatively correlated with CRP (r = −0.205),
IL-6 (r = −0.233) andWBC (r = −0.292). Moreover, depression
was associated with high IL-6 serum levels and increased cardio-
vascular mortality risk. In conclusion, in patients without heart
disease depression seems to be associated with HRV imbalance
and inflammation.
Table 3 summarizes the majority of clinical studies that
have evaluated the relationship between different inflammatory
biomarkers and HRV metrics, in patients with different cardio-
vascular diseases.
HEART RATE VARIABILITY AND SYSTEMIC INFLAMMATION
IN CRITICAL ILLNESS
The presence of sympathetic overactivity, autonomic dysfunc-
tion, inappropriately increased heart rate, insulin resistance and
in some cases, cardiomyopathy with reduced cardiac contrac-
tility, has also been observed during severe sepsis and multiple
organ failure (Muller-Werdan et al., 2006). However, in cardiac
patients sympathetic activity dominates over vagal tone where
in septic patients both branches of ANS are attenuated (Muller-
Werdan et al., 2006). For these reasons, it has been hypothesized
that during critical illness except for ANS impairment, a defec-
tive signal transduction at the level of pacemaker cells could
also account for observed differences between cardiac and septic
patients (Fairchild et al., 2009).
Alterations in HRV during septic shock and multiple organ
dysfunction syndrome (MODS), have been reported from dif-
ferent research groups (Goldstein and Buchman, 1998; Goldstein
et al., 1998; Seely and Christou, 2000). In this respect, Goldstein
et al. (1998) found that both increased total variability and LF
power were associated with recovery and survival, whereas a
decrease in total power, LF/HF and LF power correlated with
severity of illness and mortality in septic patients, 48 h after
being admitted to the Intensive Care Unit. In an animal study
of experimental endotoxemia, induced by administration of
lipopolysacchraride (LPS, endotoxin derived from the cell wall of
Gram-negative bacteria) Fairchild and colleagues demonstrated a
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Table 3 | Summary of several clinical studies investigating a possible association between HRV indices and inflammation in patients with
CAD, CHF and healthy individuals.
References Study population Duration and HRV
measures
Inflammatory
indices
Results
Hamaad et al., 2005 100 patients with acute CAD vs.
29 healthy controls
20min time, time and
frequency domain
CRP, IL-6 Negative correlation with SDNN,
VLF and LF
Lanza et al., 2006 531 patients with unstable CAD 24-h time, time and
frequency domain
CRP Inverse correlation between CRP
with SDNN and VLF
Madsen et al., 2007 269 patients with suspected CAD 24-h time, time domain CRP Upper CRP quartile negatively
correlated with SDNN
Nolan et al., 2007 29 patients with CAD 5-min time, frequency
domain
CRP HF power decreased in high CRP
group
Psychari et al., 2007 98 patients with acute CAD
(post-MI)
24-h time, time and
frequency domain
CRP Inverse relation between CRP and
SDNN, HF and LF power
von Känel et al., 2011 862 patients with CAD 24-h time, time domain CRP, IL-6, fibrinogen Inverse association between CRP,
IL-6 and SDNN
Aronson et al., 2001 64 patients with CHF 24-h time, frequency domain TNF-α, IL-6 IL-6 inversely correlated with
SDNN and ULF power
Malave et al., 2003 10 healthy controls, 15 patients
with mild CHF, 14 patients with
moderate CHF
24-h time, frequency domain TNF-α, TNF soluble
type 1 and 2
receptors
Inverse correlation between
inflammatory measures, SDNN,
LF and HF
Sajadieh et al., 2004 643 subjects without CHF 24-h time, time domain CRP, WBC Inverse correlation between
SDNN with CRP and WBC SDNN
predictor of CRP
Sloan et al., 2007 757 young healthy adults 10-min time, frequency
domain
CRP, IL-6 CRP and IL-6 inversely correlated
with HF and LF
Owen and Steptoe, 2003 211 healthy subjects 20–30min time, time domain TNF-α, IL-6 No relation between both TNF-α
and IL-6 with HRV
Lampert et al., 2008 264 healthy twins individuals 24-h time, frequency domain CRP, IL-6 Inverse relation between CRP and
IL-6 with all HRV frequency
metrics (except for HF)
Abbreviations: CRP, C-reactive protein; CAD, coronary artery disease; CHF, congestive heart failure; MI, myocardial infarction; WBC, white blood cell count.
strong inverse correlation between SDNN and total power of RR
time series and peak concentrations of different cytokines, 3–9 h
post-LPS (Fairchild et al., 2009). The same results were found
after administration of recombinant TNF-α. It was suggested that
mechanisms responsible for decrease in HRV could be related
with effects of LPS and/or cytokines on various ion channels.
Tateishi et al. (2007) investigated the relationships between
HRV and interleukin 6 upon admission in a cohort of 45 septic
patients and they found that IL-6 exhibited significant negative
correlations with both LF and HF power values. These findings
indicate a possible association between low HRV indices and
hyper-cytokinemia.
In another study Papaioannou et al. (2009), we investigated
possible associations between different HRV indices and various
biomarkers of inflammation, in 45 septic patients and during the
first 6 days of their stay in the ICU. We daily assessed HRV in
time (SDNN) and frequency domain (LF, HF and LF/HF) and
measured C-reactive protein, Interleukin 6 and 10 serum levels in
two groups of patients. The first group included subjects suffer-
ing from sepsis with mean Sequential Organ Failure Assessment
score of severity of illness (SOFA) ≤ 10 (n = 25) and the second
group included patients with septic shock (SOFA > 10, n = 20).
This study found in the group of patients with SOFA > 10, sta-
tistically significant inverse correlations between CRP and LF/HF
ratio (r = −0.61), (Figure 1A) and positive correlations with HF
(r = 0.80). At the same time, IL-10 proved to be significantly cor-
related with HF and SOFA score in a positive way and with LF,
LF/HF and SDNN in a negative way. Finally, the total variability
of heart rate signals (SDNN) was found to be negatively corre-
lated with both CRP (r = −0.79) and SOFA score (r = −0.84)
(Figure 1B). IL-6 was not significantly correlated with any HRV
parameter. It is possible that, the pleuripotency of this cytokine
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FIGURE 1 | (A) Longitudinal trends over time of mean values of CRP and
LF/HF ratio, reflecting sympathovagal balance, for patients with SOFA > 10,
during the 6 days of study period. [log transformed data, adapted from
Papaioannou et al. (2009)]. It appears that LF/HF changes inversely with
CRP. (B) Longitudinal trends over time of mean values of CRP and SDNN
(secs), for patients with SOFA > 10, during the 6 days of study period. [log
transformed data, adapted from Papaioannou et al. (2009)]. There is a
progressive increase in SOFA score from day 1 until day 4 (development of
septic shock) and a subsequent downward shift in its values. At the same
time, the variability of heart rate signals estimated with SDNN seems to be
significantly reduced during the development of septic shock.
could be responsible for our results since IL-6 can behave as both a
pro-inflammatory activator (induces the production of CRP) and
inhibitor (limits Tumor necrosis factor α and IL-1β secretion), at
the same time (Chrousos, 1995).
These findings suggest that reduction in HRV and LF/HF
is related with an augmented pro- and anti-inflammatory
response during sepsis, especially in more severely ill patients.
Furthermore, severity of illness is positively associated with HF
and IL-10 serum concentrations and changes inversely with vari-
ability of heart rate signals. In this respect, elevated levels of IL-10
have also been found in trauma patients who developed sepsis and
multiorgan failure (Sherry et al., 1996).
In conclusion, it seems that critical illness and high cytokine
levels are associated with reduced HRV, however, existing liter-
ature does not elucidate whether loss of HRV is related to an
endotoxin effect at the level of ANS output, baroreflex sensitivity
or the pacemaker cell itself. However, results from a prospec-
tive study in a group of 40 healthy adults who received a single
intravenous bolus of 2 ng/kg LPS, suggested that there is no
relationship between basal cardiac ANS activity, and the inflam-
matory response (Kox et al., 2011). Thus, no association was
found between frequency components of HRV that were deter-
mined hourly and until 8 h after LPS administration and different
pro- and anti-inflammatory cytokines, measured at various time
points. According to the authors, vagus nerve innervation of the
heart does not reflect outflow to other organs, such as the spleen,
one of the major cytokine-producing organs (Tracey, 2002, 2007).
As basal vagal input to the spleen may be different from vagal
input to the heart, HRV might not be an appropriate method
to assess activation of the cholinergic anti-inflammatory path-
way (Kox et al., 2011). These findings strengthen the notion that
autonomic outflow cannot be regarded as a general response, but
appears to be organ-specific. In this respect, results from differ-
ent studies discussed so far lack generalization and robustness due
to different study populations and design, interspecies differences
and potential impact of severity of disease, sedation ormechanical
ventilation uponHRV (Goldstein and Buchman, 1998). However,
it appears that an inverse association between inflammation and
total variability of heart rate signals could be found in the most
severe cases.
POTENTIAL THERAPEUTIC IMPLICATIONS
Different clinical trials have shown that fatty acids from fish oil
can be considered as powerful disease-modifying nutrients in
patients with acute lung injury, sepsis and cardiovascular diseases
(Christensen et al., 1999; Abuissa et al., 2005; Pontes-Arruda et al.,
2006; Singer et al., 2006). Particularly, feeding with the very-long
chain, ω-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic
acid (EPA) and docasahexaenoic acid (DHA) has been found to
inhibit the activity of the pro-inflammatory transcription factor
nuclear factor kB (NF-kB) and subsequently, to attenuate the pro-
duction of different cytokines, chemokines and other effectors of
innate immune response (Singer et al., 2008). In the cardiovas-
cular literature, it has been shown that oral supplementation of
ω-3 PUFAs increase instantaneous HRV, reduce LF/HF ratio and
confer protection against ischemia-induced ventricular tachycar-
dia and sudden cardiac death (Abuissa et al., 2005). Moreover,
Christensen (Christensen et al., 1999) demonstrated that fish oil
feeding can induce an incorporation of DHA into the membranes
of granulocytes, which is associated with a dose-response increase
in HRV (SDNN), something that may protect against serious ven-
tricular arrhythmias. Such effects of fish oil reflect an enhanced
efferent vagal activity via a central-acting mechanism, due to
a possible suppression of pro-inflammatory cytokines that have
been found to inhibit central vagal neurons (Singer et al., 2008).
Never-the-less, different interventional studies on ω-3 PUFAs
and HRV in patients with heart disease have found inconsistent
results, with only 8 out of the 20 trials published so far, sup-
porting a beneficial effect on HRV (Christensen, 2011). Indeed,
Mozaffarian et al. (2008) reported that individuals with the high-
est fish consumption (≥5 meals/week) only exhibited 1.5ms
greater HRV compared to those with the lowest fish consumption
and further that this modest reduction in HRV was associated
with only a 1.1% reduction in the relative risk for sudden cardiac
death. Reasons for such inconsistency might include heteroge-
neous populations, limited sample sizes or different study pro-
tocols with variable administered doses of ω-3 PUFA and length
of intervention. Furthermore, different methods of measurement
of HRV with variable time of recordings could be an additional
confounder. Finally, an animal study with administration of ω-3
PUFAs in rabbits showed that a reduction in pacemaker funny
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current rather than an alteration in autonomic neural regulation
was responsible for heart rate reduction and increase in HRV
(Verkerk et al., 2009). However, such experiments were performed
in denervated hearts, excluding a potential impact of autonomic
tone on HRV. More recently, the HRV response to physiological
challenges was not altered by dietary ω-3 fatty acids in con-
scious intact preparations; data that further suggest that these
lipids elicited alterations in pacemaker rate rather than cardiac
autonomic regulation (Billman and Harris, 2011; Billman, 2012).
Recent evidence suggests that HMG-CoA reductase inhibitors
(statins) have pleiotrophic mechanisms in patients with heart fail-
ure, such as ANS output modulation (Lefer, 2002). Experiments
with animal models of heart failure have found decreased
sympathetic activation and autonomic balance restoration with
statins, using HRV analysis (Pliquett et al., 2002). In a cross-
over study of HRV in 30 patients with hyperlipidemia (Welzig
et al., 2003), pravastatin administration induced a significant
increase in HF power of ECG signals, whereas others (Vrtovec
et al., 2005) found that administration of 10mg of atorvas-
tatin for 3 months, was associated with significant increase in
SDNN and RMSSD, in 80 patients with CHF and hyperlipi-
demia. Moreover, cholesterol lowering was not correlated with
HRV changes, suggesting another mechanism than that of lipid-
lowering of statins. In this context, Gao et al. (2005) showed
that in experimental heart failure states there is intense free
radical production and up-regulation of angiotensin receptors,
in autonomic areas of the brain. Moreover, simvastatin therapy
was proven to inhibit angiotensin II and superoxide pathways
in the RVLM of pacing-induced heart failure rabbits, leading
to an abolished renal sympathetic nerve activity (Gao et al.,
2005).
Different experimental studies have shown that cate-
cholamines, except from increasing cardiac contractility and
heart rate via interaction with beta adreno-receptors, may
induce myocardial damage by calcium overload and subsequent
cell necrosis, upon excessive β-adrenoreceptor stimulation
(Opie et al., 1985; Mann et al., 1992). Although, toxic cardiac
effects of catecholamines have been recognized since 1907,
Rona et al. (1959) was the first who observed that isopro-
terenol injection into rats produced “infarct-like” myocardial
necrosis, in the absence of coronary artery lesions. He pro-
posed the theory of “relative hypoxia” as a pathophysiological
mechanism, suggesting a possible imbalance between oxygen
demand and blood flow, after excessive adrenergic stimulation.
Fleckenstein (1971) thought that calcium overload was the
result of catecholamine-mediated cell injury, due to extensive
activation of Ca-dependent ATPases and subsequent high energy
phosphate deficiency, leading to mitochondrial impairment.
On the contrary, Opie and co-workers (1985) were the first
who demonstrated that catecholamine cell injury was due to
calcium overload, mediated by the β-adrenoreceptor. More
recent studies have confirmed previous results and have also
demonstrated that other mechanisms could be responsible as
well, for catecholamine-induced cell injury, such as increased
fibrosis of the left ventricle with associated hypertrophy (Briest
et al., 2001) or myocardial cellular apoptosis (Commural et al.,
1998).
Since heart failure is associated with a sympathetic up-
regulation and parasympathetic withdrawal, β blockers have been
used to modify the effects of augmented sympathetic tone and
restore autonomic imbalance. In this respect, Goldsmith et al.
(1997) showed that administration of carvedilol for 4 months was
associated with a significant increase in HF power, in patients
with CHF under digoxin and angiotensin-converting enzyme
(ACE) inhibitors. Similar results were found in post-MI sub-
jects by Lampert et al. (2003), after treatment with propranolol
for 6 weeks. An elevation in HF, which reflects restoration of
sympatho-vagal balance, was found to increase final outcome
(LVEF, exercise capacity, death and CHF development) in both
studies.
Recent evidence suggests that a primary site of attenuated vagal
control on the heart occurs at the level of the parasympathetic
gaglion (Bibevski and Dunlap, 2011). Thus, cervical vagus nerve
stimulation (VNS) has been recently assessed as an “add-on”
therapy to optimal medical management of CHF. Li and col-
leagues (2004) were the first who found that VNS performed for
10 s every minute, in rats developed HF after anterior myocar-
dial infarction, improved significantly left ventricular function
and decreased mortality from 50 to 14%, in comparison with
sham treated animals. Zhang et al. (2009) recently demonstrated
in a canine model with high rate ventricular pacing induced
HF, that VNS over 12 weeks was able to reduce left ventricular
end systolic and end-diastolic volumes and increase LVEF signifi-
cantly. In addition, HRV was significantly improved in VNS dogs
whereas plasma norepinephrine and CRP levels were markedly
attenuated with VNS treatment. Finally, vagal stimulation has also
been found to limit infarct size and inflammatory response to
myocardial ischemia and reperfusion in male rats that underwent
myocardial ischemia for 30min and reperfusion for 24 h (Calvillo
et al., 2011). According to the authors, the anti-inflammatory
and anti-apoptotic properties of the nicotinic pathway were the
primary underlying mechanism in the VNS-treated animals.
Based on the results of VNS in animal models of HF, Schwartz
et al. (2008) and De Ferrari et al. (2011) were the first who
assessed feasibility and safety and tested possible efficacy of
chronic VNS in HF patients with New York Heart Association
(NYHA) class II-IV symptoms. In a two-staged study, (8-patients
feasibility phase plus 24-patients safety and tolerability phase)
they used CardioFit, a right cervical VNS implantable system
delivering pulses synchronous with heart beats through a multi-
ple contact bipolar cuff electrode. VNSwas started 2–4 weeks after
implant and patients were followed 1, 3, and 6 months thereafter.
VNS was well tolerated whereas, there was a significant improve-
ment in NYHA class and left ventricular end-systolic volume.
Moreover, a significant increase in HRV, estimated with pNN50
and slightly but significantly reduced heart rate were found 6
months after VNS onset (Schwartz et al., 2008; De Ferrari et al.,
2011).
As a consequence of such preliminary results, a pivotal mul-
ticenter international clinical trial, the INOVATE-HF study, has
been recently designed to assess safety and efficacy of VNS in
650 CHF patients from 80 sites, with NYHA class III symp-
toms, sinus rhythm and QRS width less than 120ms, using
the CardioFit system (Hauptman et al., 2012). Thus, in case of
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significant decrease in mortality, vagal stimulation will add sig-
nificant value to current medical therapy in a narrow spectrum
of patients with heart failure, through restoration of sympatho-
vagal balance. Never-the-less, a lot of questions remain to be
addressed, such as optimal stimulation mode (i.e., right vs. left
vagus nerve stimulation, continuous vs. pulse-synchronous stim-
ulation etc) or effective and tolerable VNS dose, before adopt-
ing this new non-pharmacologic treatment to our therapeutic
armamentarium.
CONCLUSIONS AND FUTURE SUGGESTIONS
Different experimental studies have established an inter-relation
between ANS output and inflammatory regulation, whereas the
discovery of the “cholinergic anti-inflammatory pathway” has
expanded our understanding of how the nervous system mod-
ulates the inflammatory response through an immunoreflex.
Furthermore, clinical data from large epidemiological studies
involving patients with CAD, heart failure and healthy subjects
with increased risk factors for heart diseases suggest that there is a
rather weak or moderate association between inflammation and
ANS activity, estimated through HRV analysis. Finally, investiga-
tion of HRV alterations during critical illness, such as sepsis and
MODS, has demonstrated loss of variability of heart rate signals
that is inversely correlated with immune response, particularly in
most severe cases.
Early and more accurate monitoring of cardiovascular
patients, particularly in the early stages of life-threatening ill-
nesses through continuous automated detection of abnormal
variability of heart rate signals, could alert clinicians to impend-
ing clinical deterioration and allow earlier intervention. In this
respect, the combination of structural indices, such as the left
ventricular ejection fraction, with autonomic function indices
derived from heart rate variability analysis has been proposed as
the state-of-the-art method for risk assessment among patients
with acute myocardial infarction or severe congestive heart failure
(Priori et al., 2001). However, in-consistent findings from dif-
ferent studies assessing the relationship between HRV frequency
components and inflammation limit adoption of HRV analysis
as an indirect estimator of inflammatory response, since there is
a marked heterogeneity in study protocols, time and methods of
HRV measurement and patients’ characteristics. Moreover, HRV
analysis does not simply reflect sympathetic/parasympathetic bal-
ance, since HRV data can be influenced by artifacts related to
differences in breathing characteristics, genetic factors or basal
autonomic tone. Thus, any change in LF/HF ratio may corre-
spond to central, baroreflex or cellular membrane effects of dif-
ferent stimuli during severe stress. Furthermore, sympathetic out-
flow can either induce or inhibit inflammatory activity, whereas
HF component might fail to reflect vagal inputs upon different
organs, such as the spleen, which are major cytokine producers.
In addition, the explanatory power of HRV analysis is affected
by circadian variability as well as by the estimation of inflam-
matory activity through biomarkers’ measurements from a single
blood sample (Haensel et al., 2008). Finally, lack of signals’ sta-
tionarity (stable statistical properties) during measurements and
the strong association between HRV data and inflammation that
has been demonstrated among the most severely ill patients could
reflect a non-linear relationship between ANS and inflammatory
response. Thus, it has been suggested that newer methods derived
from chaos theory should be implemented to assess ANS output,
such as fractal and detrended fluctuation analysis (DFA) of heart
rate signals (Goldberger, 1996). In addition, standardization of
experimental protocols and methods used for the estimation of
HRV is urgently needed, in order to allow comparisons among
different studies.
In conclusion, the enormous complexity of neuro-
immunological interactions cannot be captured by simple
measurements, such as HRV analysis. A rather multi-parameter
monitoring of ANS, through different estimators of heart rate
variability and complexity has been suggested for assessment
of ANS output (Goldberger, 1996). In any case and since HRV
metrics are not enough for differentiating between patho-
physiological states (poor specificity) or between patients (poor
sensitivity), longitu-dinal alterations over time of both HRV and
inflammatory markers on an intra-individual basis must be tested
for establishing a potential added value of HRV analysis, as an
indirect estimator of inflammatory response (Papaioannou et al.,
2009).
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